Publicaciones en colaboración con investigadores/as de Hospital de Terrassa (20)

2023

  1. QT interval and short-term outcome in acute heart failure

    Clinical Research in Cardiology, Vol. 112, Núm. 12, pp. 1754-1765

2022

  1. Ambient temperature and atmospheric pressure at discharge as precipitating factors in immediate adverse events in patients treated for decompensated heart failure

    Internal and Emergency Medicine, Vol. 17, Núm. 7, pp. 2045-2056

  2. Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study

    Minerva Anestesiologica, Vol. 88, Núm. 4, pp. 259-271

2021

  1. Correction to: Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study (Clinical Research in Cardiology, (2021), 110, 7, (993-1005), 10.1007/s00392-020-01710-0)

    Clinical Research in Cardiology

  2. Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study

    Clinical Research in Cardiology, Vol. 110, Núm. 7, pp. 993-1005

  3. Parestomal hernia repair. Prospective observational study based on the Spanish Registry of Incisional Hernia (EVEREG)

    Cirugia Espanola, Vol. 99, Núm. 7, pp. 527-534

  4. Profile of patients who visit medical internists for an osteoporosis assessment: The OSTEOMED registry

    Revista Clinica Espanola, Vol. 221, Núm. 1, pp. 9-17

  5. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome

    European heart journal, Vol. 42, Núm. 33, pp. 3127-3142

  6. The FAST-FURO study: Effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 5, pp. 487-496

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

  2. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 67, Núm. 8, pp. 425-437

2019

  1. Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1353-1365

  2. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  3. Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles

    Microbial Pathogenesis, Vol. 128, pp. 112-118

2018

  1. Improved empirical antibiotic treatment of sepsis after an educational intervention: The ABISS-Edusepsis study

    Critical Care, Vol. 22, Núm. 1

2017

  1. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2014

  1. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin

    Journal of Antimicrobial Chemotherapy

2012

  1. Antibiotic prescription patterns in the empiric therapy of severe sepsis: Combination of antimicrobials with different mechanisms of action reduces mortality

    Critical Care, Vol. 16, Núm. 6

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492